MedPath

Use of Penthrox in Extra-hospital Traumatology

Completed
Conditions
Pain, Acute
Pain Management
Trauma Injury
Interventions
Other: Penthrox
Registration Number
NCT03537001
Lead Sponsor
University Hospital, Tours
Brief Summary

In pre-hospital settings, the administration of analgesics is often delayed because of difficult patient access (incarceration), difficulty finding a venous pathway or patient refusal.

An optimization of the management of pain in urgency is therefore still necessary.

A side from nitrousoxide of which usage remains restrictive, methoxyflurane (Penthrox®) is the only volatile analgesic currently available for pre-hospital use.

The purpose of this study is to answer the question: Does the use of the inhaled route with Penthrox add value to the treatment of acute traumatic pain in the pre-hospital stage?

Detailed Description

In pre-hospital settings, the administration of analgesics is often delayed because of difficult patient access (incarceration), difficulty finding a venous pathway or patient refusal.

An optimization of the management of pain in urgency is therefore still necessary.

A side from nitrousoxide of which usage remains restrictive, methoxyflurane (Penthrox®) is the only volatile analgesic currently available for pre-hospital use.

Methoxyflurane (Penthrox®) is a single-use inhalation non-opioid analgesic for the management of moderate to severe traumatic pain. This treatment has been used in New Zealand and Canada for over 20 years for the management of acute pain in adults and children. It was granted marketing authorization in Europe in 2016 and has been marketed in France since 2017.

The purpose of this study is:

* To study the efficacy and safety of Penthrox, administrated at the beginning of the management of the traumatized adult patient.

* Assess the comfort of patients and caregivers

* To answer the question: Does the use of the inhaled route with Penthrox add value to the treatment of acute traumatic pain in the pre-hospital stage?

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Conscious Patient
  • Age ≥ 18 years
  • Acute pain only of traumatic origin
  • Pain > 4 on a visual numerical scale (VNS)
  • Stable hemodynamic conditions (PA> 90/60)

Non Inclusion Criteria:

  • Pregnant or nursing woman
  • Patient who has already received analgesics
  • Patient benefiting from an intravenous approach for analgesia
  • Known renal or hepatic disease
  • Hypersensitivity to fluorinated anesthetics or history of malignant hyperthermia of the patient or family.
  • Respiratory distress
  • Patient who objected to the processing of his data
Exclusion Criteria
  • Intravenous injection for analgesia

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
PenthroxPenthroxAdministration of Penthrox at the beginning of the management of the traumatized adult patient
Primary Outcome Measures
NameTimeMethod
Change of traumatic acute pain level between baseline and 5 minutesBaseline, 5 minutes

Efficiency will be measured by its effect on pain according to a visual numerical scale (VNS: between 0 and 10).

Secondary Outcome Measures
NameTimeMethod
Pain extinction durationBaseline, 10 & 15 minutes

Duration before pain extinction, evaluated using a visual numerical scale (VNS: between 0 and 10) at 0, 10 \& 15 minutes.

Change of traumatic acute pain level between 0 and15 minutesBaseline, 15 minutes

Efficiency will be measured by its effect on pain according to a visual numerical scale (VNS: between 0 and 10).

Change of traumatic acute pain level between baseline and 10 minutesBaseline, 10 minutes

Efficiency will be measured by its effect on pain according to a visual numerical scale (VNS: between 0 and 10).

Penthrox toleranceThrough study completion, an average of 30 minutes

Collection of side effects

Medical team level of satisfaction30 minutes

5 grades satisfaction scale filled by the medical team 30 minutes after the treatment (Very satisfied, Satisfied, Neutral, Dissatisfied, Very dissatisfied)

Patient level of satisfaction30 minutes

5 grades satisfaction scale filled by the patient 30 minutes after the treatment (Very satisfied, Satisfied, Neutral, Dissatisfied, Very dissatisfied)

Trial Locations

Locations (1)

Emergency Medical Service, University Hospital, Tours

🇫🇷

Tours, France

© Copyright 2025. All Rights Reserved by MedPath